Taiwan beats Japan and South Korea to PIC/S membership

19 October 2012

Taiwan’s Food and Drug Administration of the Department of Health has finally succeeded in knocking the gate into the Pharmaceutical Inspection Convention and Co-operation Scheme (PIC/S) international organization ahead of Japan and South Korea, and Taiwan will become an official member of the PIC/S from January 1 of next year (2013), according to a posting on the Taipei Representative Office in the European Union web site.

This not only means that Taiwan will be able to share information on international pharmaceutical safety to ensure public drug safety, but also demonstrates the international approval of the Good Manufacturing Practices (GMP) regulations, management systems and auditing standards of domestic pharmaceutical companies, which will significantly improve the international image of the country and enhance the international competitiveness of our domestic pharmaceutical industries, the statement notes.

Expected to attract foreign investment and pharma expand exports

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics